Literature DB >> 2818598

The methylation pattern in the 5' end of the human estrogen receptor gene is tissue specific and related to the degree of gene expression.

R Piva1, L V Kumar, S Hanau, I Maestri, A P Rimondi, S F Pansini, G Mollica, P Chambon, L del Senno.   

Abstract

Restriction enzyme mapping has been used to study the relationship between methylation at the 5' end of the human estrogen receptor gene (ER) and its various levels of expression in estrogen target tissues, like endometrium, placenta and breast. The methylation patterns were compared with that found in white blood cells. A cluster of CpG sites, including the transcription start site, was undermethylated in all examined tissues. In front and downstream of this area, a 1 Kb region was undermethylated in endometrium where the ER gene is highly expressed, methylated to some extent in placenta and breast, which express the gene to a low degree, and greatly methylated in white blood cells which are thought not to express this gene. These data provide evidence that in the 5' end of the human ER DNA, CpG methylation is tissue-specific, and related to the level of the ER gene expression.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2818598

Source DB:  PubMed          Journal:  Biochem Int        ISSN: 0158-5231


  3 in total

1.  A transcriptional enhancer required for the differential expression of the human estrogen receptor in breast cancers.

Authors:  Z Tang; I Treilleux; M Brown
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

Review 2.  The silent estrogen receptor--can we make it speak?

Authors:  Madhavi Billam; Abigail E Witt; Nancy E Davidson
Journal:  Cancer Biol Ther       Date:  2009-03-15       Impact factor: 4.742

3.  Different methylation of oestrogen receptor DNA in human breast carcinomas with and without oestrogen receptor.

Authors:  R Piva; A P Rimondi; S Hanau; I Maestri; A Alvisi; V L Kumar; L del Senno
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.